This still puts Merck near the top of the venerable firm's holdings in the pharma space, by dollar weighting. Here is the morning's full text SEC filing -- on Schedule 13G.
This is reduced from the zenith -- at 7 per cent -- breached last year, this time. But as I say, still respectable. Very. . . respectable:
Here is last year's item on this -- for perspective. Off to enjoy a foggy, London style Monday morning.
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjZfsC2q5187Z5knmWecokEsNY6Y4aqXthTTSSq0_RYeKryD04iZ__qAnz3XV9WG-yTWQIhbi1ZMPsFMrZh-P1gl2YnlD4Dzy9rSxPldIpLBqhZ6Rsihlv87ulhdOhxjlYfclnNe2Wd5bMS/s200/SGP-namaste-big.jpg)
No comments:
Post a Comment